There are new options for chronic hepatitis B treatment

recently, at the "Conquering the New Choice of Hepatitis B" academic conference held in Shanghai by Schering Yuya Pharmaceutical Company,
Professor Cheng Jun, Vice Chairman of the Association of Infections of the Chinese Medical Association and Vice President of theof Beijing DitanHospital, was deeply pleased with the recent approval of polyethylene glycol interferon (alpha-2b-Pereon) for the treatment of hepatitis B in China for many hepatitis B patientsChengjun said that in the nearly 20 years since the advent of ordinary interferon, the effect of its treatment of hepatitis B has been recognizedHowever, the common interference is known to have a disadvantage, is small molecules, injection soon after the kidneys "leak" out of the body, 12 hours after the injection of interferon in the body is almost completely excretedTo maintain efficacy, patients have to inject common interferon three times a week or once every other day, which is not only inconvenient, but also durable for the virusTo overcome this shortcoming, the scientists found in the study that binding a substance called polyglycol in common interferons can make the interferon molecules larger and prevent interferons from being excreted from the kidneysBut the study also shows that the greater the molecular weight of polyethylene glycol, the longer the half-life, the fewer the number of administrations, its antiviral activity will be lower and lowerTherefore, the selection of polyglycol molecular weight should not only consider the ability to extend the half-life, so that it can be administered once a week, but also consider the maximum retention of its antiviral activityTo achieve this balance, the researchers repeatedly designed and optimized the molecular weight of polyglycol to 12KD, thus achieving an in vitro antiviral activity that was more than 25 times higher than the long-acting interferon alpha-2aAn international multi-center clinical trial led by Professor Harry L.AJanssen of the University of Rotterdam Medical Center in the Netherlands showed that HBeAg-positive patients with HBeAg-positive hBeAg treatment with polyglycol interferon had an e-antigen transficional rate of 36% in the first half of the treatmentIn particular, patients treated with polyglycol interferon alone, if e antigen transnegative, 19% of patients with hepatitis B virus surface antigen (HbsAg) will also turn yin, which is currently the closest to hepatitis B "cure"standardClinical trials conducted in China showed that polyglycol interferon was 10% higher than the response rate of common interferon"The B genotype and the C genotype are the two dominant gene types in patients with hepatitis B in China, " Cheng said Clinical trials have shown that for these patients, polyglycol interferon showed significant e-antigen transcides Some patients who meet certain criteria, such as younger, low baseline viral hepatitis B patients with a B gene, respond better to polyglycol interferon; "
in the of adverse drug reactions, Cheng Jun believes that it is very important to control the amount of drug use He points out that one of the
common adverse reactions of common interferon is bone marrow inhibition, which manifests itself as a decline in white blood cells or platelets after injection of interferon Patients with severe bone marrow suppression will have to reduce the dose or stop the drug, which will affect the efficacy Polyglycol interferon, as the only long-acting interferon administered by weight, realized the goal of minimizing the of adverse reactions and maximizing the efficacy In addition, due to the optimal design of polyglycol interferon molecular weight retains 30% of the kidney removal rate, so that the drug can be quickly removed from the body after discontinuation, when the occurrence of significant bone marrow inhibition, can also easily adjust the dose of the drug (reproduced from China Medical Daily)